IL17A and neoplasm: Established 4T1 tumor burden was significantly reduced in mice treated with celecoxib (P < 0.05), α-IL-17 antibody (P < 0.01), or celecoxib + α-IL-17 antibody (P < 0.01) when compared with untreated or control antibody + vehicle (DMSO) treated mice (Figure 6i).